# A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

> **NCT01047345** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 924 (actual)

## Conditions studied

- Cervical Cancers
- Vulvar Cancers
- Vaginal Cancers
- Genital Warts

## Interventions

- **BIOLOGICAL:** V503
- **BIOLOGICAL:** Placebo to V503

## Key facts

- **NCT ID:** NCT01047345
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02-24
- **Primary completion:** 2011-06-10
- **Final completion:** 2015-11-28
- **Target enrollment:** 924 (ACTUAL)
- **Last updated:** 2018-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01047345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01047345, "A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01047345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*